According to Cushman & Wakefield, Avila Therapeutics has leased 23,000 s/f at 45 Wiggins Ave. Cushman & Wakefield's director, Juliette Reiter, along with executive director, Mark Winters, and senior director, David Townsend, represented Avila Therapeutics.
Owned, managed and operated by Alexandria Real Estate Equities, Inc., 45 Wiggins Ave. is a single-story 38,000 s/foffice and laboratory building. This move represents a net growth for Avila Therapeutics which will be relocating from Alexandria Real Estate Equities' 100 Beaver St. in Waltham.
Avila Therapeutics is a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs. This approach is called "protein silencing." The company's product pipeline has been built using its proprietary Avilomics(tm) platform, and Avila's most advanced product candidate, AVL-292, is currently in Phase 1 clinical testing. AVL-292 is a highly selective inhibitor of Bruton's tyrosine kinase and is a potential treatment for cancer and autoimmune diseases. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners and has established strategic alliances with Sanofi, Clovis Oncology, Novartis Option Fund, and the Leukemia & Lymphoma Society.
"Avila is a very exciting, life science company which has recently doubled in size." said Reiter "With Alexandria providing such a high-level of laboratory support and infrastructure, Avila Therapeutics was pleased that it could grow within the Alexandria portfolio."